TAVALISSE logo
TAVALISSE Payer Coverage

TAVALISSE is preferred on major national commercial formularies, and more than 97% of commercially insured patients in the US will have coverage.1 More information, including details about coverage local to your practice and your patients, is available from our representatives.

Rigel offers services and support for PATIENTS WITH ITP

With TAVALISSE Copay Assistance, eligible patients pay as little as $15 per prescription fill

TAVALISSE copay card thumbnail

  • Visit TAVALISSEcopay.com to enroll and verify eligibility
  • Eligible patients can use their TAVALISSE Patient Copay Assistance Card to reduce their prescription costs whether they receive their medication from a specialty pharmacy or from their physician's in-house pharmacy

Patients may qualify* if . . .

  • They have been diagnosed with low platelet counts due to chronic immune thrombocytopenia (ITP) when a prior treatment for ITP has not worked well enough
  • They are 18 years of age or older
  • They have a commercial insurance plan
  • They are not participating in state or federal programs like Medicare Part D, Medicaid, VA/DOD, or Tricare or other state or federal assistance plans

Limitations may apply.*

*Eligible patients, age 18 or older and with a valid prescription, may receive TAVALISSE at a $15 copay for each prescription fill, if they pay through commercial insurance. The patient will be responsible for any out-of-pocket expenses after the $25,000 annual cap. This offer is not valid for cash-paying patients. This offer is not insurance and offer is valid only for prescriptions filled in the United States and Puerto Rico. Rigel reserves the right to rescind, revoke, or amend this program without notice. Other restrictions may apply. Patient is responsible for applicable taxes, if any.

ENROLL YOUR PATIENTS IN THE COPAY ASSISTANCE PROGRAM NOW

RIGEL ONECARE PROVIDES SUPPORT SO PATIENTS CAN ACCESS TAVALISSE

RIGEL ONECARE helps patients get started with TAVALISSE by

  • Providing resources that may support your office with the reimbursement process, including benefit investigations, prior authorizations, and appeals
  • Determining eligibility and facilitating enrollment in patient support programs such as Copay Assistance or Patient Assistance
  • Contacting patients and answering their questions so they start TAVALISSE with the information they need

RIGEL ONECARE helps patients stay on track by

  • Connecting with patients during the first weeks of their treatment to provide additional support as requested
  • Supporting modifications in treatment plans and notifying you if a patient has stopped treatment or has a medical concern
  • Ensuring continuity of treatment if a patient’s insurance coverage changes

RIGEL ONECARE expertise is designed to fit within your practice needs

  • Expert: RIGEL ONECARE nurses are fully trained and dedicated to supporting patients who have been prescribed TAVALISSE
  • Flexible: RIGEL ONECARE can provide support whether TAVALISSE is fulfilled through in-office dispensing or through specialty pharmacies
  • Customized: Choose RIGEL ONECARE services and method of contact based on what works best for your staff and your patients

Download the TAVALISSE Enrollment and Patient Assistance Program Form to get started with RIGEL ONECARE.

RIGEL ONECARE is a patient support center sponsored by Rigel Pharmaceuticals, Inc.

  • Nurse iconNurse Navigators
  • Talking about money iconReimbursement
    Specialists
  • Payment iconFinancial and
    Copay Assistance

Download the RIGEL ONECARE ENROLLMENT FORM

phone

1-833-rigelOC

(1-833-744-3562) or 650-449-8646

MONDAY-FRIDAY FROM 8 am – 8 pm ET

 

Fax1-833-FXrigel

(1-833-397-4435) or 650-449-8682

tavalisse together provides your patients with insights, tips, and motivation to help them achieve their goals

TAVALISSE TOGETHER is a program for adult patients with chronic immune thrombocytopenia (ITP) who are taking or are interested in taking TAVALISSE. This program partners with patients throughout their treatment journey, helping them to become successful with their ITP treatment and achieve their goals.

TAVALISSE TOGETHER builds upon the information you may be sharing with your patients. The more patients know about ITP, what to expect with treatment, and how to get the most out of conversations with their healthcare team, the better prepared they’ll be to stay on track.

Enrolled patients will receive:

  • Insights icon

    Insights and motivation to help patients with a smooth start and long-term success with TAVALISSE, by developing habits to take TAVALISSE as prescribed

  • Info Icon

    Advice on overcoming treatment obstacles, like if they miss a dose or if a side effect happens

  • Wrench icon

    Tools to help patients set goals for their treatment and lifestyle, and ways to help them discuss their goals with you

Whether your patients are just getting started or they’re already taking TAVALISSE, TAVALISSE TOGETHER is here to help them fit their ITP treatment seamlessly into daily life.

PATIENTS CAN GET STARTED NOW AT TAVALISSETOGETHER.COM

TAVALISSE TOGETHER is a trademark of Rigel Pharmaceuticals, Inc.

Reference: 1. Data on file, Rigel Pharmaceuticals, Inc. Managed Markets Insight & Technology, LLC. Coverage current as of June 2022.

TAVA_ITP-22111 0722

Indication and Important Safety Information

Indication

TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Important Safety Information

Warnings and Precautions

  • Hypertension can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly, and adjust or initiate antihypertensive therapy for blood pressure control maintenance during therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation may be required.
  • Elevated liver function tests (LFTs), mainly ALT and AST, can occur with TAVALISSE. Monitor LFTs monthly during treatment. If ALT or AST increase to ≥3 x upper limit of normal, manage hepatotoxicity using TAVALISSE interruption, reduction, or discontinuation.
  • Diarrhea occurred in 31% of patients and severe diarrhea occurred in 1% of patients treated with TAVALISSE. Monitor patients for the development of diarrhea and manage using supportive care measures early after the onset of symptoms. If diarrhea becomes severe (≥Grade 3), interrupt, reduce dose or discontinue TAVALISSE.
  • Neutropenia occurred in 6% of patients treated with TAVALISSE; febrile neutropenia occurred in 1% of patients. Monitor the ANC monthly and for infection during treatment. Manage toxicity with TAVALISSE interruption, reduction, or discontinuation.
  • TAVALISSE can cause fetal harm when administered to pregnant women. Advise pregnant women the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the last dose. Verify pregnancy status prior to initiating TAVALISSE. It is unknown if TAVALISSE or its metabolite is present in human milk. Because of the potential for serious adverse reactions in a breastfed child, advise a lactating woman not to breastfeed during TAVALISSE treatment and for at least 1 month after the last dose.

Drug Interactions

  • Concomitant use of TAVALISSE with strong CYP3A4 inhibitors increases exposure to the major active metabolite of TAVALISSE (R406), which may increase the risk of adverse reactions. Monitor for toxicities that may require a reduction in TAVALISSE dose.
  • It is not recommended to use TAVALISSE with strong CYP3A4 inducers, as concomitant use reduces exposure to R406.
  • Concomitant use of TAVALISSE may increase concentrations of some CYP3A4 substrate drugs and may require a dose reduction of the CYP3A4 substrate drug.
  • Concomitant use of TAVALISSE may increase concentrations of BCRP substrate drugs (eg, rosuvastatin) and P-Glycoprotein (P-gp) substrate drugs (eg, digoxin), which may require a dose reduction of the BCRP and P-gp substrate drug.

Adverse Reactions

  • Serious adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which occurred in 1% of TAVALISSE patients. In addition, severe adverse reactions occurred including dyspnea and hypertension (both 2%), neutropenia, arthralgia, chest pain, diarrhea, dizziness, nephrolithiasis, pain in extremity, toothache, syncope, and hypoxia (all 1%).
  • Common adverse reactions (≥5% and more common than placebo) from FIT-1 and FIT-2 included: diarrhea, hypertension, nausea, dizziness, ALT and AST increased, respiratory infection, rash, abdominal pain, fatigue, chest pain, and neutropenia.

 

Please see full Prescribing Information.

To report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Back to the top

Rigel Pharmaceuticals logo

© 2022 Rigel Pharmaceuticals, Inc. All rights reserved.  TAVA_ITP-22110 0722

TAVALISSE and RIGEL ONECARE are registered trademarks and TAVALISSE TOGETHER is a trademark of Rigel Pharmaceuticals, Inc.

RIGEL ONECARE is a patient support center sponsored by Rigel Pharmaceuticals, Inc.

1180 Veterans Blvd, South San Francisco, CA 94080

This site is intended for US healthcare professionals only.

Indication and Important Safety Information

Indication

TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Important Safety Information

Warnings and Precautions

  • Hypertension can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly, and adjust or initiate antihypertensive therapy for blood pressure control maintenance during therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation may be required.
TAVALISSE logo

September is ITP Awareness month

Join Rigel in helping to raise awareness of immune thrombocytopenia (ITP) and showing support for ITP patients, care partners, and healthcare providers

TAVA_ITP-20158 0920